Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis (MScog-tDCS)
Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis / Améliorer Les capacités Cognitives Par tDCS Chez Les Patients Souffrants de sclérose en Plaques
Sponsor: Teva Pharmaceuticals USA
Terminated
lack of recruitement
Other terminated trials from Teva Pharmaceuticals USA
Other Cognitive Deficits trials with similar outcome
Listed as NCT02266121, this NA trial focuses on Cognitive Deficits and Motor Deficits and remains terminated or withdrawn. Sponsored by Teva Pharmaceuticals USA, it has been updated 11 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jun 2023 — Jul 2024 [monthly]
Terminated NA
Status: Suspended → Terminated
-
May 2021 — Jun 2023 [monthly]
Suspended NA
-
Jan 2021 — May 2021 [monthly]
Suspended NA
▶ Show 6 earlier versions
-
May 2020 — Jan 2021 [monthly]
Suspended NA
-
Nov 2018 — May 2020 [monthly]
Suspended NA
Status: Recruiting → Suspended
-
Jul 2018 — Nov 2018 [monthly]
Recruiting NA
-
Jun 2018 — Jul 2018 [monthly]
Recruiting NA
-
Jul 2017 — Jun 2018 [monthly]
Recruiting NA
-
Jan 2017 — Jul 2017 [monthly]
Recruiting NA
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Teva Pharmaceuticals USA
- University Hospital of Mont-Godinne
- Université Catholique de Louvain
For direct contact, visit the study record on ClinicalTrials.gov .